Trial · NCT00520286

Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence

NCT00520286, Phase 2, Completed, National Institute on Drug Abuse (NIDA); results first posted 2017-04-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence. Trials, record NCT00520286. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00520286

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT number: NCT00520286
Status: Completed
Phases: Phase 2
Enrollment: 210 participants, actual
Lead sponsor: National Institute on Drug Abuse (NIDA)
Conditions: Methamphetamine Dependence
Interventions: Modafinil, Placebo
First posted: 2007-08-24
Last updated: 2017-04-07
Results first posted: 2017-04-07

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Abstinence (Week 1 - 12)	Weeks 1 - 12	Number of participant who abstained from methamphetamine from weeks 1 through 12
Secondary	Reduction of Craving	21 days	Number of subjects with 21 or more consecutive days of abstinence

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Abstinence (Week 1 - 12)	Weeks 1 - 12		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Reduction of Craving	21 days		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Abstinence (Week 1 - 12)	Modafinil	Week 1	27	Participants
Abstinence (Week 1 - 12)	Placebo	Week 1	14	Participants
Abstinence (Week 1 - 12)	Modafinil	Week 2	38	Participants
Abstinence (Week 1 - 12)	Placebo	Week 2	13	Participants
Abstinence (Week 1 - 12)	Modafinil	Week 3	39	Participants
Abstinence (Week 1 - 12)	Placebo	Week 3	13	Participants
Abstinence (Week 1 - 12)	Modafinil	Week 4	46	Participants
Abstinence (Week 1 - 12)	Placebo	Week 4	15	Participants
Abstinence (Week 1 - 12)	Modafinil	Week 5	41	Participants
Abstinence (Week 1 - 12)	Placebo	Week 5	16	Participants

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Modafinil	142
Overall Study	STARTED	Placebo	68
Overall Study	COMPLETED	Modafinil	76
Overall Study	COMPLETED	Placebo	36
Overall Study	NOT COMPLETED	Modafinil	66
Overall Study	NOT COMPLETED	Placebo	32

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Modafinil	60	142	175
other	Headache	Nervous system disorders	Placebo	30	68	63
other	Nausea	Gastrointestinal disorders	Modafinil	23	142	32
other	Nausea	Gastrointestinal disorders	Placebo	8	68	13
other	Hypertension	Vascular disorders	Modafinil	55	142	104
other	Hypertension	Vascular disorders	Placebo	23	68	60
serious	Leg infection	Infections and infestations	Modafinil	0	142	0
serious	Leg infection	Infections and infestations	Placebo	1	68	1
serious	Suicidal Ideation	Psychiatric disorders	Modafinil	0	142	0
serious	Suicidal Ideation	Psychiatric disorders	Placebo	1	68	1

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Modafinil
Total, all-cause mortality	Placebo
Total, other adverse events	Modafinil	128	142
Total, other adverse events	Placebo	54	68
Total, serious adverse events	Modafinil	0	142
Total, serious adverse events	Placebo	5	68

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21840138	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Modafinil vs Placebo: Reduction of Craving	Trial comparisons
Modafinil vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00520286

GET https://conductscience.org/api/trials/v1/NCT00520286/results?page=2

API reference For AI assistants